AGYS stock sentiment todayAgilysys Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
AGYS
Agilysys IncAgilysys is a high-growth SaaS leader in hospitality transition, but current margin compression and rich valuation suggest a 'wait for the dip' scenario.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for AGYS. Not financial advice.
Price · last 12 months
Gossip
The narrative is currently a tug-of-war between impressive top-line guidance raises and immediate earnings misses. While analysts are upgrading the stock due to 2027 revenue targets, investors are reacting to short-term margin pressure and minor insider selling by Director John Mutch.
- ·Raised FY2027 revenue guidance
- ·Q2 EPS miss vs. consensus
- ·Transition from legacy licenses to SaaS recurring revenue
- ·Optimism regarding hospitality tech modernization cycles
Financial
Fundamentally robust with zero debt and a strong cash position. Revenue growth remains double-digit (16-18% YoY), but the pivot to a full SaaS model is temporarily weighing on margins as implementation costs outpace subscription recognition.
- ·P/E Ratio: ~90x (Highly elevated)
- ·Revenue Growth: 16.5% YoY
- ·Debt-to-Equity: 0.0 (Debt free)
- ·Subscription Revenue: ~60% of total revenue
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·Insiders sold a net $23.1M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High valuation leaves little room for execution errors
- ·Margin contraction due to increased R&D and sales spending
- ·Sensitivity to hospitality sector CAPEX cycles
- ·Slow conversion of professional services to high-margin recurring revenue
Peer temperature
How direct competitors stack up against AGYS right now.
- HOTORCLOracle Corporation
HOTTER — Dominates the enterprise hospitality space (Opera) with a much lower forward P/E and massive AI-cloud tailwinds.
See full analysis → - NEUTRALPARPAR Technology
NEUTRAL — Similar transition to SaaS-first model but focuses on restaurants over hotels, carrying higher volatility and less stable net income.
See full analysis → - COLDSABRSabre Corp
COLDER — Burdened by a heavy debt load and slower growth in legacy distribution systems compared to AGYS’s modern cloud stack.
See full analysis →
- AGYS+19.3%
- ORCL-4.8%
- PAR+28.4%
- SABR-23.6%
Analyst price target
Consensus average of 5 analysts · median 140.00
Source: StockAnalysis.com · updated 2026-10-27
Recent headlines
- Yahoo FinanceAgilysys (AGYS) Stock Slips As Q2 Results Put Margins In Focus
- Investing.comAgilysys director John Mutch sells $86,222 of common stock.
- Simply Wall StWill Raised 2027 Guidance Change Agilysys Stock Narrative
- MoomooAgilysys (AGYS) Releases Q2 2027 Earnings: Revenue Growth but EPS Miss
- Yahoo FinanceIs Raised Guidance Altering The Investment Case For Agilysys Stock (AGYS)?
- Yahoo FinanceAgilysys (AGYS) Could Be 8% Undervalued Following Raised Full Year Guidance
AI-generated analysis for informational purposes only. Not financial advice.